Lin C.-L.JIA-HORNG KAO2021-09-042021-09-0420130929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879158955&doi=10.1016%2fj.jfma.2013.02.001&partnerID=40&md5=f84ff6e611c965cc84945f22ada00ebchttps://scholars.lib.ntu.edu.tw/handle/123456789/582002Baseline and on-treatment hepatitis B viral factors are reported to affect treatment responses. A lower baseline hepatitis B virus (HBV) DNA level is a strong predictor of the response to antiviral therapy. HBV genotype A/B patients have better responses to interferon-based therapy than those with genotypes C/D. Regarding the association of HBV mutants with responses to antiviral therapy, current evidence is limited. On-treatment viral suppression is the most important predictor of response to nucleoside analogs. On-treatment hepatitis B surface antigen decline is significantly associated with response to pegylated interferon. In the future, individualized therapy should be based on treatment efficacy, adverse effects, baseline and on-treatment predictors of antiviral therapy. ? 2012, Elsevier Taiwan LLC & Formosan Medical Association.Antiviral therapy; Chronic hepatitis B; Hepatitis B virus DNA; Nucleos(t)ide analogs; Pegylated interferon; Quantitative HBsAg[SDGs]SDG3adefovir; adefovir dipivoxil; alanine aminotransferase; alpha interferon; creatinine; entecavir; hepatitis B surface antigen; lamivudine; peginterferon alpha; peginterferon alpha2a; peginterferon alpha2b; telbivudine; tenofovir disoproxil; virus DNA; antiviral resistance; antiviral therapy; clinical effectiveness; competitive inhibition; creatinine blood level; disease association; disease exacerbation; drug efficacy; drug half life; genotype; hepatitis B; Hepatitis B virus; human; liver cirrhosis; monotherapy; mutational analysis; nephrotoxicity; predictive value; review; risk factor; seroconversion; side effect; treatment duration; treatment response; viremia; virus strain; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant ProteinsReview10.1016/j.jfma.2013.02.001237870072-s2.0-84879158955